|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
WO2004022096A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component c5
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
|
CN102558352A
(zh)
|
2003-06-27 |
2012-07-11 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
|
CA2667894A1
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
EA201001467A1
(ru)
|
2008-03-14 |
2011-06-30 |
Биокон Лимитед |
Моноклональное антитело и способ его использования
|
|
RU2011101969A
(ru)
|
2008-06-30 |
2012-08-10 |
Ново Нордиск А/С (DK) |
Антитела к человеческому интерлейкину-20
|
|
CN104119438A
(zh)
*
|
2009-01-29 |
2014-10-29 |
米迪缪尼有限公司 |
延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
|
|
AR076640A1
(es)
*
|
2009-03-06 |
2011-06-29 |
Genentech Inc |
Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
|
|
GB0904214D0
(en)
*
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
EP2427497B1
(fr)
|
2009-05-07 |
2016-12-07 |
Stallergenes |
Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
|
|
US8454956B2
(en)
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
|
AU2010320515B2
(en)
*
|
2009-11-20 |
2013-05-02 |
Biocon Limited |
Formulations of antibody
|
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
PT3501499T
(pt)
*
|
2010-02-11 |
2022-11-22 |
Ablynx Nv |
Métodos e composições para a preparação de aerossóis
|
|
BR112012021576A2
(pt)
*
|
2010-02-26 |
2016-10-25 |
Novo Nordisk As |
composições estáveis contendo anticorpo.
|
|
BR112012027361A2
(pt)
*
|
2010-04-27 |
2021-04-27 |
Scil Technology Gmbh |
formulação mia/cd-rap estável.
|
|
RU2012153786A
(ru)
*
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
PE20141162A1
(es)
|
2010-11-04 |
2014-09-18 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-23
|
|
TWI732259B
(zh)
|
2010-12-16 |
2021-07-01 |
美商建南德克公司 |
關於th2抑制作用之診斷及治療
|
|
US20130344074A1
(en)
|
2011-03-16 |
2013-12-26 |
Sanofi |
Uses of a dual v region antibody-like protein
|
|
ES2676205T3
(es)
|
2011-03-31 |
2018-07-17 |
Merck Sharp & Dohme Corp. |
Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
UY34105A
(es)
*
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
|
EP2734236A4
(en)
*
|
2011-07-13 |
2015-04-15 |
Abbvie Inc |
METHOD AND COMPOSITIONS FOR TREATING ASTHMA WITH ANTI-IL-13 ANTIBODIES
|
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
|
RU2665810C2
(ru)
|
2011-10-31 |
2018-09-04 |
Дженентек, Инк. |
Содержащие антитела составы
|
|
EP4039275A1
(en)
*
|
2012-05-03 |
2022-08-10 |
Boehringer Ingelheim International GmbH |
Anti-il-23p19 antibodies
|
|
PE20150190A1
(es)
*
|
2012-06-21 |
2015-02-13 |
Ucb Pharma Sa |
Formulacion farmaceutica
|
|
US9221904B2
(en)
|
2012-07-19 |
2015-12-29 |
National Cheng Kung University |
Treatment of osteoarthritis using IL-20 antagonists
|
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
TWI679019B
(zh)
*
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
|
|
CA2920368C
(en)
|
2013-07-23 |
2023-03-21 |
Centro De Inmunologia Molecular |
Use of a cd6 binding partner and method based thereon
|
|
JP6463361B2
(ja)
|
2013-09-08 |
2019-01-30 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
|
|
EP4331605A3
(en)
|
2013-09-13 |
2024-05-22 |
F. Hoffmann-La Roche AG |
Methods and compositions comprising purified recombinant polypeptides
|
|
ES2915378T3
(es)
|
2013-09-13 |
2022-06-22 |
Hoffmann La Roche |
Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
|
|
SG11201603127WA
(en)
|
2013-10-23 |
2016-05-30 |
Genentech Inc |
Methods of diagnosing and treating eosinophilic disorders
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
IL310015B2
(en)
|
2013-12-31 |
2026-02-01 |
Access To Advanced Health Inst |
Single vial formulation
|
|
JP2017507939A
(ja)
|
2014-02-21 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
EP3172339A1
(en)
|
2014-07-24 |
2017-05-31 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
|
UA123624C2
(uk)
|
2014-09-03 |
2021-05-05 |
Бьорінґер Інґельхайм Інтернаціональ Ґмбх |
Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
CR20170164A
(es)
|
2014-10-24 |
2017-08-29 |
Merck Sharp & Dohme |
Coagonistas de los receptores de glucagón y de glp-1
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
JP2018500380A
(ja)
*
|
2014-12-31 |
2018-01-11 |
ノベルメド セラピューティクス，インコーポレーテッド |
アグリコシル化治療用抗体の製剤
|
|
CN107206081A
(zh)
|
2015-02-04 |
2017-09-26 |
勃林格殷格翰国际有限公司 |
治疗炎性疾病的方法
|
|
EP3271723A1
(en)
|
2015-03-16 |
2018-01-24 |
F. Hoffmann-La Roche AG |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
KR101808234B1
(ko)
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
|
JP2018535242A
(ja)
*
|
2015-11-30 |
2018-11-29 |
メディミューン，エルエルシー |
高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比
|
|
KR102799807B1
(ko)
|
2015-12-30 |
2025-04-24 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
KR102460040B1
(ko)
|
2016-04-27 |
2022-11-01 |
애브비 인코포레이티드 |
항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
KR102557643B1
(ko)
|
2016-09-23 |
2023-07-20 |
제넨테크, 인크. |
아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
|
|
PL3529274T3
(pl)
|
2016-10-21 |
2024-09-09 |
Biocon Limited |
Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
KR20200012823A
(ko)
|
2017-02-01 |
2020-02-05 |
예일 유니버시티 |
이뇨제 내성의 치료
|
|
BR112019018022A2
(pt)
*
|
2017-03-01 |
2020-06-02 |
Medimmune Limited |
Formulações de anticorpos monoclonais
|
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
|
MA48461A
(fr)
|
2017-04-28 |
2020-03-04 |
Amgen Inc |
Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
|
|
JOP20190260A1
(ar)
*
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
UA125971C2
(uk)
*
|
2017-07-25 |
2022-07-20 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
|
|
KR20200044066A
(ko)
*
|
2017-08-22 |
2020-04-28 |
바이오젠 엠에이 인코포레이티드 |
항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
|
|
IL272773B2
(en)
*
|
2017-08-22 |
2024-06-01 |
Biogen Ma Inc |
Pharmaceutical preparations containing anti-amyloid cell antibodies
|
|
CA3087699A1
(en)
|
2018-01-05 |
2019-07-11 |
Corvidia Therapeutics, Inc. |
Methods for treating il-6 mediated inflammation without immunosuppression
|
|
AU2019218128A1
(en)
|
2018-02-09 |
2020-09-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
|
MX2020009152A
(es)
|
2018-03-02 |
2020-11-09 |
Kodiak Sciences Inc |
Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
|
|
US20210223262A1
(en)
*
|
2018-06-07 |
2021-07-22 |
Merck Sharp & Dohme Corp. |
Lyosphere critical reagent kit
|
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
KR102885113B1
(ko)
|
2018-10-18 |
2025-11-13 |
머크 샤프 앤드 돔 엘엘씨 |
항-rsv 항체의 제제 및 그의 사용 방법
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
WO2020092015A1
(en)
|
2018-11-02 |
2020-05-07 |
University Of Rochester |
Therapeutic mitigation of epithelial infection
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
KR102735988B1
(ko)
|
2019-02-18 |
2024-12-03 |
일라이 릴리 앤드 캄파니 |
치료 항체 제제
|
|
CN109771398B
(zh)
*
|
2019-02-25 |
2019-09-20 |
广州南鑫药业有限公司 |
一种帕拉米韦溶液型吸入剂及其制备方法
|
|
JP7813222B2
(ja)
*
|
2019-08-16 |
2026-02-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
高濃度抗ｃ５製剤
|
|
US12577297B2
(en)
|
2019-09-09 |
2026-03-17 |
Boehringer Ingelheim International Gmbh |
Anti-IL-23p19 antibody formulations
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
JP7730817B6
(ja)
*
|
2019-12-20 |
2025-09-26 |
アレス トレーディング ソシエテ アノニム |
ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物
|
|
CN115397394A
(zh)
*
|
2020-01-31 |
2022-11-25 |
赛诺菲 |
抗体的肺部递送
|
|
CN115697403A
(zh)
*
|
2020-03-10 |
2023-02-03 |
迪赞纳生命科学公开有限公司 |
Il-6/il-6r抗体的组合物及其使用方法
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
AU2021278562A1
(en)
|
2020-05-29 |
2022-12-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing formulation
|
|
CN114870008A
(zh)
*
|
2021-02-05 |
2022-08-09 |
百奥泰生物制药股份有限公司 |
一种抗il-5抗体制剂及其制备方法和应用
|
|
WO2023044313A1
(en)
|
2021-09-15 |
2023-03-23 |
Dermira, Inc. |
Il-13 inhibitors for the treatment of prurigo nodularis
|
|
EP4662230A1
(en)
|
2023-02-08 |
2025-12-17 |
ImmunOs Therapeutics AG |
Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa
|
|
WO2025128984A1
(en)
|
2023-12-14 |
2025-06-19 |
Dermira, Inc. |
Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
|
|
WO2025128990A1
(en)
|
2023-12-14 |
2025-06-19 |
Dermira, Inc. |
Il-13 antibodies for the treatment of perennial allergic rhinitis
|
|
TW202600591A
(zh)
|
2024-03-01 |
2026-01-01 |
美商德米拉股份有限公司 |
用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體
|